At Tris Pharma, we are committed to utilizing innovative technology to bring together people, experience, and support programs to optimally serve those affected by attention deficit hyperactivity disorder (ADHD)—from patients and caregivers to healthcare professionals.
Click below to learn more about our family of branded products for the treatment of ADHD in people 6 years and older:
DYANAVEL XR, Quillivant XR, and QuilliChew ER are federally controlled substances (CII) because they can be abused or lead to dependence. Keep DYANAVEL XR, Quillivant XR, and QuilliChew ER in a safe place to prevent misuse and abuse. Selling or giving away DYANAVEL XR, Quillivant XR, and QuilliChew ER may harm others, and is against the law.
Tell your doctor if you, your child, or any family members have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
Tris Pharma ADHD products use LiquiXR® technology
We have used our innovative technology to offer patients with ADHD a range of treatment options. With LiquiXR® drug delivery technology, a healthcare provider can offer flexible dosing options to patients 6 years and older diagnosed with ADHD, allowing them to choose from 3 available product options.
Please see additional Important Safety Information and Medication Guide at the links within each product card above.
DYANAVEL and LiquiXR® are registered trademarks of Tris Pharma, Inc. Quillivant XR and Quillichew ER are registered trademarks of NextWave Pharmaceuticals, Inc.
NextWave Pharmaceuticals, Inc. is a wholly owned subsidiary of Tris Pharma, Inc.
© 2020 Tris Pharma, Inc. All rights reserved. DXR.410.PR 04/20
Interested in learning more about our products, pipeline, and partnerships?